Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 659 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Prostate Radiation Clear all
Recruiting Phase 2 Interventional

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

NCT07150715
View directory record Official record
Conditions
Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma
Interventions
Actinium Ac 225 Vipivotide Tetraxetan, Biospecimen Collection, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, PSMA PET-CT Scan, Stereotactic Body Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 27, 2026, 1:13 AM EDT
Active, not recruiting Not applicable Interventional

Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate

NCT01508390
View directory record Official record
Conditions
Prostate Cancer
Interventions
CyberKnife Boost
Radiation
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 27, 2026, 1:13 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

External Immobilization Compared to Limited Immobilization Using a Novel Real-time Localization System of the Prostate

NCT01588938
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
U.S. Army Medical Research Acquisition Activity
Federal
Eligibility
40 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 27, 2026, 1:13 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Low Intensity Shockwave Therapy for Erectile Dysfunction

NCT04434352
View directory record Official record
Conditions
Erectile Dysfunction, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Radiation Therapy, Erectile Dysfunction Due to General Medical Condition, Erectile Dysfunction Due to Arterial Insufficiency
Interventions
Storz Duolith Low-Intensity Shockwave Therapy
Device
Lead sponsor
University of Virginia
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

Hypofractionated Stereotactic Body Radiation Therapy (SBRT)

NCT01288534
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Sacramento, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 27, 2026, 1:13 AM EDT
Recruiting Phase 1 Interventional

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT07581184
View directory record Official record
Conditions
Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC, B7H3
Interventions
[225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
Drug
Lead sponsor
Aktis Oncology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Irvine, California • Miami, Florida • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 27, 2026, 1:13 AM EDT
Completed No phase listed Observational

Participation in Procurement of Tissue, Serum, Plasma, Cell Bank, DNA and RNA Samples, and Urine for Biological Studies Related to Prostate Cancer and Prostate Cancer Treatment Follow Up

NCT01098552
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
4,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2013 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Phase 1 Interventional

Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

NCT02064036
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Stereotactic Radiosurgical Boost, Casodex, Leuprolide
Radiation · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 27, 2026, 1:13 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer

NCT02508636
View directory record Official record
Conditions
Prostatic Neoplasms, Pelvic Nodal
Interventions
Enzalutamide, Leuprolide, Intensity-Modulated Radiation Therapy
Drug · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 27, 2026, 1:13 AM EDT
Active, not recruiting Not applicable Interventional

High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)

NCT02177292
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Not applicable Interventional

Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer

NCT00003045
View directory record Official record
Conditions
Prostate Cancer
Interventions
Hyperthermia, XRT
Device · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 27, 2026, 1:13 AM EDT
Active, not recruiting Phase 2 Interventional

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

NCT03902951
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Apalutamide, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 27, 2026, 1:13 AM EDT
Recruiting Phase 2 Interventional

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

NCT06526299
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Lutetium Lu 177 Vipivotide Tetraxetan, Magnetic Resonance Imaging, PSMA PET-CT Scan, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
San Francisco, California • Sylmar, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 27, 2026, 1:13 AM EDT
Recruiting Phase 3 Interventional

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

NCT07548164
View directory record Official record
Conditions
Prostate Cancer
Interventions
NanoKnife System, Stereotactic Body Radiation Therapy
Device · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

NCT01807065
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Soft Tissue Metastases, Stage IV Prostate Cancer
Interventions
sipuleucel-T, external beam radiation therapy, laboratory biomarker analysis
Biological · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Duarte, California • Pasadena, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 1:13 AM EDT
Terminated Not applicable Interventional

Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer

NCT05224869
View directory record Official record
Conditions
Prostate Cancer
Interventions
Medical Device Usage and Evaluation, CT simulation, Stereotactic body radiation therapy, Brachytherapy, Post-implant dosimetry scan
Device · Procedure · Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 27, 2026, 1:13 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

NCT00430183
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, LHRH agonist, surgery
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
221
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Berkeley, California + 166 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 27, 2026, 1:13 AM EDT
Withdrawn Phase 2 Interventional

Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)

NCT04569461
View directory record Official record
Conditions
Prostate Cancer
Interventions
pembrolizumab, Low dose prostate radiation, Radical Prostatectomy
Drug · Radiation · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 27, 2026, 1:13 AM EDT
Recruiting Phase 2 Interventional

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

NCT05915442
View directory record Official record
Conditions
Oligometastatic Prostate Cancer
Interventions
Quemliclustat, Etrumadenant, Zimberelimab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Catherine Spina
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

Metformin Prostate Cancer Adjuvant Trial

NCT02176161
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Recurrent
Interventions
Metformin Hydrochloride Extended Release 750mg
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Not applicable Interventional Results available

PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer

NCT04220983
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
MR-Guided Prostate SBRT
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 27, 2026, 1:13 AM EDT
Recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

NCT04175431
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Positron Emission Tomography, Lymphadenectomy, Radiation Therapy, Abiraterone Acetate, Prednisone, Computed Tomography, Abiraterone, PSMA PET Scan
Procedure · Radiation · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2037
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer

NCT02280356
View directory record Official record
Conditions
Prostate Cancer
Interventions
external beam radiation therapy, brachytherapy, questionnaires
Radiation · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 27, 2026, 1:13 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.

NCT05148156
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Urolift
Device
Lead sponsor
Northwell Health
Other
Eligibility
50 Years to 99 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Syosset, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 1:13 AM EDT